Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
about
Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells
description
article
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у 2018
@uk
name
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@en
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@nl
type
label
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@en
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@nl
prefLabel
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@en
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@nl
P2093
P2860
P356
P1476
Evidence That Combination Ther ...... r in CD4+ CD2hi Memory T Cells
@en
P2093
Amanda G Tomalka
Daniel L Popkin
Ivelisse Resto-Garay
Kerry S Campbell
P2860
P356
10.3389/FIMMU.2018.02552
P407
P577
2018-01-01T00:00:00Z